AVEO Pharmaceuticals logo
AVEO Pharmaceuticals AVEO

Quarterly report 2022-Q3
added 11-07-2022

report update icon

AVEO Pharmaceuticals Cash Flow 2011-2025 | AVEO

Annual Cash Flow AVEO Pharmaceuticals

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

-57.3 M -38 M -2.92 M -25 M -19.2 M -31.1 M - - -84.4 M -106 M 26.5 M

Depreciation & Amortization

67 K 21 K - - - 30 K 9.57 M 6.22 M 3.78 M 2.51 M 1.65 M

Accounts Payables

2.71 M 3.38 M 1.47 M 3.5 M 2.44 M 2.19 M 1.42 M 3.24 M 4.24 M 10.6 M 8.9 M

Accounts Receivables

9.81 M 1.2 M 1.63 M 3.03 M 402 K 1.03 M 4.64 M 2.34 M 984 K 20.6 M 7.21 M

Total Inventories

1.66 M - - - - - - - - - -

All numbers in USD currency

Quarterly Cash Flow AVEO Pharmaceuticals

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

- -10.5 M - -8.22 M - -45.1 M - -18.3 M - -25.1 M -19.2 M -11.7 M - 4.45 M -14.5 M -8.46 M - -18.4 M -15.6 M -6.52 M - -15.4 M -12.4 M - - - - - - - - - - - - -19.8 M - - - -21.6 M - -82.4 M -58.3 M -30.6 M - 46.4 M 45.5 M 92.9 M

Depreciation & Amortization

- 51 K - 17 K - 51 K - 17 K - 9 K 4 K - - - - - - - - - - - - - - 7 K 7 K 5 K - 9.56 M 9.46 M 4.49 M - 2.76 M 1.69 M 838 K - 2.84 M 1.87 M 900 K - 1.75 M 1.15 M 546 K - 1.2 M 765 K 372 K

Accounts Payables

- 5.04 M - 3.01 M 2.71 M 4.92 M 3.16 M 3.96 M 3.38 M 3.38 M 3.38 M 3.38 M 1.47 M 1.47 M 1.47 M 1.47 M 3.5 M 3.5 M 3.5 M 3.5 M 2.44 M 2.44 M 2.44 M 2.44 M 2.19 M 2.19 M 2.19 M 2.19 M 1.42 M 1.42 M 1.42 M 1.42 M 3.24 M 3.24 M 3.24 M 3.24 M 4.24 M 4.24 M 4.24 M 4.24 M 10.6 M 10.6 M 10.6 M 10.6 M 8.9 M 8.9 M 8.9 M 8.9 M

Accounts Receivables

- 18.7 M - 12.9 M 9.81 M 8.3 M 4.22 M 1.14 M - - 1.21 M 1.2 M 1.63 M 1.63 M 1.63 M 1.63 M 3.03 M 3.03 M 3.03 M 3.03 M 402 K 402 K 402 K 402 K 1.03 M 1.03 M 1.03 M 1.03 M 4.64 M 4.64 M 4.64 M 4.64 M 2.34 M 2.34 M 2.34 M 2.34 M 984 K 984 K 984 K 984 K 20.6 M 20.6 M 20.6 M 20.6 M 7.21 M 7.21 M 7.21 M 7.21 M

Total Inventories

- 1.11 M - 1.69 M 1.66 M 1.25 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company AVEO Pharmaceuticals, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.9 4.03 % $ 813 M canadaCanada
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Aclaris Therapeutics Aclaris Therapeutics
ACRS
$ 3.21 -1.38 % $ 248 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Aptevo Therapeutics Aptevo Therapeutics
APVO
$ 1.06 -6.22 % $ 293 K usaUSA
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 13.33 -5.39 % $ 878 M usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 214.55 -2.66 % $ 5 B danmarkDanmark
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.1 -5.93 % $ 7.46 B australiaAustralia
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 27.09 -1.53 % $ 1.74 M usaUSA
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
$ 88.51 0.59 % $ 9.14 B usaUSA
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
$ 24.35 3.07 % $ 2.88 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
CureVac N.V. CureVac N.V.
CVAC
$ 5.02 -0.59 % $ 934 M germanyGermany
BioVie BioVie
BIVI
$ 1.43 -1.72 % $ 2.11 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
BioNTech SE BioNTech SE
BNTX
$ 93.99 -0.86 % $ 27.2 B germanyGermany
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
$ 10.88 0.74 % $ 1.41 B usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 26.44 4.63 % $ 1.28 B usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 9.6 0.42 % $ 141 M usaUSA
Eton Pharmaceuticals Eton Pharmaceuticals
ETON
$ 15.97 -4.37 % $ 410 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 0.26 -6.9 % $ 566 M israelIsrael
Evogene Ltd. Evogene Ltd.
EVGN
$ 1.04 -3.7 % $ 27.9 M israelIsrael
Exelixis Exelixis
EXEL
$ 41.27 0.95 % $ 12 B usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Foghorn Therapeutics Foghorn Therapeutics
FHTX
$ 4.39 -1.13 % $ 241 M usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Axon Enterprise Axon Enterprise
AXON
$ 551.37 -2.29 % $ 41.8 B usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Aytu BioScience Aytu BioScience
AYTU
$ 2.35 2.17 % $ 14.8 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
$ 91.19 1.51 % $ 96.9 B britainBritain
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 8.88 -1.33 % $ 1.45 B britainBritain
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$ 11.25 -2.43 % $ 728 M usaUSA
Biogen Biogen
BIIB
$ 174.69 0.34 % $ 25.4 B usaUSA